Global CAR T therapy trial shows high rates of durable remission for NHL

(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah ™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577). Results from the single-site study, with follow-up extending past two years, will be published today in the New England Journal of Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news